Department of Otolaryngology-Head and Neck Surgery, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI, USA.
Head Neck. 2010 Aug;32(8):1040-7. doi: 10.1002/hed.21285.
For patients with advanced laryngeal cancer, a trial was designed to determine if chemotherapy alone, in patients achieving a complete histologic complete response after a single neoadjuvant cycle, was an effective treatment with less morbidity than concurrent chemoradiotherapy.
Thirty-two patients with advanced laryngeal or hypopharyngeal cancer received 1 cycle of induction chemotherapy, and subsequent treatment was decided based on response.
A histologic complete response was achieved in 4 patients and were treated with chemotherapy alone. All 4 patients' cancer relapsed in the neck and required surgery and postoperative radiotherapy (RT). Twenty-five patients were treated with concomitant chemoradiation. Three patients were treated with surgery. Overall survival and disease-specific survival at 3 years were 68% and 78%, respectively.
Chemotherapy alone is not feasible for long-term control of regional disease in patients with advanced laryngeal cancer even when they achieve a histologic complete response at the primary site.
对于晚期喉癌患者,设计了一项试验,以确定对于单一新辅助周期后完全组织学完全缓解的患者,单独化疗是否比同期放化疗更有效,且发病率更低。
32 例晚期喉或下咽癌患者接受了 1 个周期的诱导化疗,随后根据反应决定治疗方案。
4 例患者获得了组织学完全缓解,仅接受了化疗。这 4 例患者的癌症均在颈部复发,需要手术和术后放疗(RT)。25 例患者接受了同期放化疗。3 例患者接受了手术治疗。3 年时的总生存率和疾病特异性生存率分别为 68%和 78%。
即使在原发部位达到组织学完全缓解,单独化疗也不能长期控制晚期喉癌患者的区域疾病。